Search This Blog

Tuesday, September 15, 2026

Cogent Biosciences gets FDA acceptance of bezuclastinib NDA in advanced systemic mastocytosis

 

 PDUFA date set for June 29, 2027

  • FDA currently does not plan to convene an advisory committee meeting for the bezuclastinib NDA review.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)